Close Close Comment Creative Commons Donate Email Add Email Facebook Instagram Facebook Messenger Mobile Podcast Print RSS Search Secure Twitter WhatsApp YouTube

Katie Thomas

Memorial Sloan Kettering Leaders Violated Conflict-of-Interest Rules, Report Finds

A policy review follows months of turmoil at the cancer center, which pledged an overhaul, including new rules on public disclosure and limits on outside profits.

Memorial Sloan Kettering Curbs Executives’ Ties to Industry After Conflict-of-Interest Scandals

The cancer center will now bar top officials from sitting on outside boards of for-profit companies, and is conducting a wide-scale review of other policies.

Top Cancer Doctor, Forced Out Over Ties to Drug Makers, Joins Their Ranks

AstraZeneca has hired Dr. José Baselga, the former chief medical officer at Memorial Sloan Kettering, to lead its cancer research unit.

Memorial Sloan Kettering’s Season of Turmoil

One of the nation’s top cancer hospitals has grappled with how to bring breakthrough treatments to market while remaining true to its mission.

Top Cancer Doctor Resigns as Editor of Medical Journal

Dr. José Baselga, the former chief medical officer of Memorial Sloan Kettering Cancer Center, was asked to resign after he failed to disclose corporate ties in dozens of scientific articles.

Prominent Doctors Aren’t Disclosing Their Industry Ties in Medical Journal Studies. And Journals Are Doing Little to Enforce Their Rules

The dean of Yale’s medical school, the incoming president of a prominent cancer group and the head of a Texas cancer center are among leading medical figures who have not accurately disclosed their relationships with drug companies.

Sloan Kettering Cancer Researchers Correct the Record by Revealing Company Ties

The hospital’s chief medical officer resigned last month after failing to disclose company ties in medical journals. Now, Memorial Sloan Kettering researchers, including chief executive Dr. Craig B. Thompson, are updating their own conflict-of-interest disclosures.

Memorial Sloan Kettering’s Chief Executive Resigns From Merck’s Board of Directors

Under scrutiny for the hospital’s industry ties and compensation, Dr. Craig B. Thompson stepped down from two company boards.

Cancer Center’s Board Chairman Faults Top Doctor, Saying He “Crossed Lines”

The executive told Memorial Sloan Kettering staff that the hospital did not do enough to limit the industry conflicts of its chief medical officer, who has resigned.

Facing Crisis, Sloan Kettering Tells Exec to Hand Over Profits From Biotech

A vice president at Memorial Sloan Kettering received a stake of nearly $1.4 million in a biotech company for representing the hospital on its board. He will give back his stake as the cancer center grapples with questions about conflicts of interest.

Cancer Center Switches Focus on Fundraising as Problems Mount

The change highlights the challenges facing Memorial Sloan Kettering, one of the nation’s most prestigious cancer centers, amid a widening crisis.

Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar

A for-profit venture with exclusive rights to use the cancer center’s vast archive of tissue slides has generated concerns among pathologists at the hospital, as well as experts in nonprofit law and corporate governance.

Top Official at Memorial Sloan Kettering Resigns After Failing to Disclose Industry Ties

Dr. José Baselga, the hospital’s chief medical officer, stepped down days after a report by ProPublica and the New York Times that he failed to disclose millions of dollars in payments from the health care and drug industry in research articles.

Sloan Kettering Cancer Center Orders Staff to “Do a Better Job” of Disclosing Industry Ties

The move comes after ProPublica and The New York Times reported that one of its top executives failed to report payments from drug and health care companies in dozens of medical journal articles.

Top Cancer Researcher Fails to Disclose Corporate Financial Ties in Major Research Journals

A senior official at Memorial Sloan Kettering Cancer Center has received millions of dollars in payments from companies that are involved in medical research. His omissions expose how weakly conflict-of-interest rules are enforced by journals.

The Price They Pay

ProPublica and The New York Times have partnered to tell the stories of Americans living daily with the reality of high-cost drugs. There are millions of others just like them.

When Buying Prescription Drugs, Some Pay More With Insurance Than Without It

As insurers ask consumers to pay a greater share of their drug costs, it may be cheaper to pay cash than use your insurance card. One expert estimates that consumers could be overpaying for as many as 1 in 10 prescriptions.

How to Save Money on Your Prescription Drugs

Online prescription sites may help you find cheaper prices for some drugs, sometimes without using your insurance.

Why Are Drug Prices So High? We’re Curious, Too.

The New York Times and ProPublica have teamed up to investigate who is to blame for skyrocketing drug prices — and have turned up some surprising answers.

Amid Opioid Crisis, Insurers Restrict Pricey, Less Addictive Painkillers

Drug companies and doctors have been accused of fueling the opioid crisis, but some question whether insurers have played a role, too.

Follow ProPublica

Latest Stories from ProPublica

Close this

Journalism That Holds Power to Account

Sign up for ProPublica’s Big Story newsletter and get our latest stories delivered straight to your inbox.

Current site Current page